JPMorgan Chase & Co. Cuts BioNTech (NASDAQ:BNTX) Price Target to $122.00

BioNTech (NASDAQ:BNTX) had its target price trimmed by JPMorgan Chase & Co. from $124.00 to $122.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other brokerages have also recently weighed in on BNTX. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and raised their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. UBS Group lifted their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. Finally, Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $138.67.

BioNTech Trading Up 1.8 %

NASDAQ:BNTX opened at $120.72 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a one year low of $76.53 and a one year high of $131.49. The company has a market cap of $28.94 billion, a PE ratio of -57.49 and a beta of 0.26. The firm has a 50-day moving average of $113.52 and a 200-day moving average of $98.35.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same period in the previous year, the company posted $0.73 EPS. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, equities research analysts expect that BioNTech will post -3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently made changes to their positions in BNTX. Planning Capital Management Corp boosted its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. boosted its position in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after acquiring an additional 252 shares during the period. GAMMA Investing LLC grew its stake in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after acquiring an additional 238 shares in the last quarter. Finally, Clear Harbor Asset Management LLC bought a new stake in BioNTech during the 3rd quarter worth approximately $210,000. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.